Chronic oral etoposide

Trials at Indiana University and with the Hoosier Oncology Group

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recent availability of an oral formulation, formed the basis for several trials at Indiana University and through the Hoosier Oncology Group. These trials evaluated chronic daily administration of the drug in several malignancies. In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy. In small cell lung cancer, etoposide demonstrated activity in both previously treated and untreated patients. The drug, however, had little impact on patients with advanced non-small cell lung cancer, advanced melanoma, or advanced soft tissue sarcoma. Since etoposide appears to be most effective in refractory small cell lung cancer and germ cell tumors, we believe the drug should be explored in tumors with a known history of chemosensitivity to conventionally administered etoposide.

Original languageEnglish
Pages (from-to)48-52
Number of pages5
JournalSeminars in Oncology
Volume19
Issue number6 SUPPL. 14
StatePublished - 1992

Fingerprint

Etoposide
Small Cell Lung Carcinoma
Germ Cell and Embryonal Neoplasms
Appointments and Schedules
Pharmaceutical Preparations
Neoplasms
Testicular Neoplasms
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Sarcoma
Melanoma
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Chronic oral etoposide : Trials at Indiana University and with the Hoosier Oncology Group. / Loehrer, Patrick.

In: Seminars in Oncology, Vol. 19, No. 6 SUPPL. 14, 1992, p. 48-52.

Research output: Contribution to journalArticle

@article{56a72a1752cf4f2e928733f49af33b42,
title = "Chronic oral etoposide: Trials at Indiana University and with the Hoosier Oncology Group",
abstract = "Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recent availability of an oral formulation, formed the basis for several trials at Indiana University and through the Hoosier Oncology Group. These trials evaluated chronic daily administration of the drug in several malignancies. In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy. In small cell lung cancer, etoposide demonstrated activity in both previously treated and untreated patients. The drug, however, had little impact on patients with advanced non-small cell lung cancer, advanced melanoma, or advanced soft tissue sarcoma. Since etoposide appears to be most effective in refractory small cell lung cancer and germ cell tumors, we believe the drug should be explored in tumors with a known history of chemosensitivity to conventionally administered etoposide.",
author = "Patrick Loehrer",
year = "1992",
language = "English",
volume = "19",
pages = "48--52",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 14",

}

TY - JOUR

T1 - Chronic oral etoposide

T2 - Trials at Indiana University and with the Hoosier Oncology Group

AU - Loehrer, Patrick

PY - 1992

Y1 - 1992

N2 - Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recent availability of an oral formulation, formed the basis for several trials at Indiana University and through the Hoosier Oncology Group. These trials evaluated chronic daily administration of the drug in several malignancies. In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy. In small cell lung cancer, etoposide demonstrated activity in both previously treated and untreated patients. The drug, however, had little impact on patients with advanced non-small cell lung cancer, advanced melanoma, or advanced soft tissue sarcoma. Since etoposide appears to be most effective in refractory small cell lung cancer and germ cell tumors, we believe the drug should be explored in tumors with a known history of chemosensitivity to conventionally administered etoposide.

AB - Etoposide has proven to be an active agent in the treatment of a variety of neoplasms, particularly germ cell cancers and small cell lung cancer. Yet despite its widespread use, the optimal dose and schedule for etoposide remain unknown. The fact that its efficacy appears to be schedule dependent, along with the recent availability of an oral formulation, formed the basis for several trials at Indiana University and through the Hoosier Oncology Group. These trials evaluated chronic daily administration of the drug in several malignancies. In testicular cancer, etoposide was shown to have a possible role in adjuvant therapy for refractory disease or as part of combination chemotherapy. In small cell lung cancer, etoposide demonstrated activity in both previously treated and untreated patients. The drug, however, had little impact on patients with advanced non-small cell lung cancer, advanced melanoma, or advanced soft tissue sarcoma. Since etoposide appears to be most effective in refractory small cell lung cancer and germ cell tumors, we believe the drug should be explored in tumors with a known history of chemosensitivity to conventionally administered etoposide.

UR - http://www.scopus.com/inward/record.url?scp=0027069507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027069507&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 48

EP - 52

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 14

ER -